1
|
Zeng J, Zheng Y, Dong S, Ding T, Zhang S, Li K, Liu H, Fang Q, Yuan S, Wei Y, Li J, Liu T. Andrographolide inhibits Burkitt's lymphoma by binding JUN and CASP3 proteins. Cancer Chemother Pharmacol 2024; 93:381-391. [PMID: 38148335 PMCID: PMC10950985 DOI: 10.1007/s00280-023-04626-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Accepted: 11/24/2023] [Indexed: 12/28/2023]
Abstract
BACKGROUND Burkitt's lymphoma, one of the most common subtypes of pediatric malignant lymphoma, is notorious for its swift onset, aggressive proliferation, pronounced invasiveness, and marked malignancy. The therapeutic landscape for Burkitt's lymphoma currently falls short of providing universally effective and tolerable solutions. Andrographolide, a primary active component of Andrographis paniculata, is renowned for its properties of heat-clearing, detoxification, inflammation reduction, and pain relief. It is predominantly used in treating bacterial and viral infections of the upper respiratory tract, as well as dysentery. Various reports highlight the antitumor effects of andrographolide. Yet, its specific impact and the underlying mechanism of action on Burkitt's lymphoma remain an uncharted area of research. METHOD We employed network pharmacology to pinpoint the targets of andrographolide's action on Burkitt's lymphoma and the associated pathways. We then evaluated the impact of andrographolide on Burkitt's lymphoma using both in vitro and in vivo patient-derived xenograft (PDX) models. Concurrently, we confirmed the molecular targets of andrographolide in Burkitt's lymphoma through immunofluorescence assays. RESULT Utilizing network pharmacology, we identified 15 relevant targets, 60 interrelationships between these targets, and numerous associated signaling pathways for andrographolide's action on Burkitt's lymphoma. In vitro efficacy tests using High-throughput Drug Sensitivity Testing and in vivo PDX model evaluations revealed that andrographolide effectively curtailed the growth of Burkitt's lymphoma. Moreover, we observed a increased in the expression of JUN (c-Jun) and CASP3 (Caspase 3) proteins in Burkitt's lymphoma cells treated with andrographolide. CONCLUSION Andrographolide inhibits the growth of Burkitt's lymphoma by inhibiting JUN and CASP3 proteins.
Collapse
Affiliation(s)
- Junquan Zeng
- Department of Hematology, The Affiliated Hospital of Jinggangshan University, Ji'an, 343000, China
| | - Yongliang Zheng
- Department of Hematology, The Affiliated Hospital of Jinggangshan University, Ji'an, 343000, China
| | - Si Dong
- Department of Hematology, The Affiliated Hospital of Jinggangshan University, Ji'an, 343000, China
- First Clinical Medical College, Gannan Medical University, Ganzhou, 341000, China
| | - Ting Ding
- Department of Hematology, The Affiliated Hospital of Jinggangshan University, Ji'an, 343000, China
| | - Shouhua Zhang
- Department of General Surgery, The Affliated Children's Hospital of Medical College, Nangchang, 330000, China
| | - Kuangfan Li
- Department of General Surgery, The Affliated Children's Hospital of Medical College, Nangchang, 330000, China
| | - Haiyun Liu
- Department of Laboratory, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nangchang, 330000, China
| | - Quangang Fang
- Department of Laboratory, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nangchang, 330000, China
| | - Sheng Yuan
- Department of Pathology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nangchang, 330000, China
| | - Yujing Wei
- Department of Hematology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, No. 1666, Diezihu Avenue, Nangchang, 330000, Jiangxi, China
| | - Jing Li
- Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, 29208, USA
| | - Tingting Liu
- Department of Hematology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, No. 1666, Diezihu Avenue, Nangchang, 330000, Jiangxi, China.
| |
Collapse
|